CASC3 Antibody
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-56306
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Rabbit IgG
Concentration
0.5 mg/ml
Product Specifications
Immunogen
Synthetic peptides corresponding to CASC3(cancer susceptibility candidate 3) The peptide sequence was selected from the N terminal of CASC3.
Peptide sequence MADRRRQRASQDTEDEESGASGSDSGGSPLRGGGSCSGSAGGGGSGSLPS. The peptide sequence for this immunogen was taken from within the described region.
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Description
The addition of 50% glycerol is optional for those storing this antibody at -20C and not aliquoting smaller units. However, please note that glycerol may interrupt some downstream antibody applications and should be added with caution.
Scientific Data Images for CASC3 Antibody
Western Blot: CASC3 Antibody [NBP1-56306]
Western Blot: CASC3 Antibody [NBP1-56306] - ACHN cell lysate, concentration 0.2-1 ug/ml.Applications for CASC3 Antibody
Application
Recommended Usage
Western Blot
1.0 ug/ml
Formulation, Preparation, and Storage
Purification
Affinity purified
Formulation
PBS, 2% Sucrose
Preservative
0.09% Sodium Azide
Concentration
0.5 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: CASC3
Alternate Names
barentsz, Btz, cancer susceptibility candidate 3, Cancer susceptibility candidate gene 3 protein, metastatic lymph node 51, Metastatic lymph node gene 51 protein, MLN 51, MLN51BTZ, Protein barentsz, protein CASC3
Gene Symbol
CASC3
UniProt
Additional CASC3 Products
Product Documents for CASC3 Antibody
Product Specific Notices for CASC3 Antibody
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...